Concepedia

Author

Aida Hanjalic-Beck

University Medical Center Freiburg

Also Known As

A Hanjalic-Beck, A. Hanjalic-Beck, A. Hanjalic‐Beck, Aida Hanjalic-Beck, Hanjalic-Beck, Aida

30

Publications

548

Citations

10

H-Index

28

Concepts

All Affiliations

University Medical Center FreiburgUniversity of FreiburgHeidelberg UniversityGerman Cancer Research Center
AH

About

Aida Hanjalic-Beck is an author at University Medical Center Freiburg specializing in obstetrics, medicine, and pharmacology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

4

4

124

2

Public Health

2

2

35

3

Social Sciences

1

1

60

4

Cell Biology

1

1

29

5

Endocrinology

1

1

29

Aida Hanjalic-Beck

×

8

Publications

275

Citations

8

H-Index

YearCitations

Three‐dimensional ultrasound for the assessment of breast lesions

Dirk Watermann, M Földi, Aida Hanjalic-Beck,

Ultrasound in Obstetrics and Gynecology

2005

65

The impact of chemotherapy for breast cancer on sexual function and health-related quality of life

Juliane Farthmann, Aida Hanjalic-Beck, J. Veit,

Supportive Care in Cancer

2016

60

Critical evaluation of human endometrial explants as an ex vivo model system: a molecular approach

William R Schafer, Lara Fischer, Katrin Roth,

Molecular Human Reproduction

2010

38

In vitro-Ishikawa cell test for assessing tissue-specific chemical effects on human endometrium

Wolfgang R. Schaefer, Lara Fischer, W.R. Deppert,

Reproductive Toxicology

2010

29

Metformin<i>versus</i>acarbose therapy in patients with polycystic ovary syndrome (PCOS): a prospective randomised double-blind study

Aida Hanjalic-Beck, Boris Gabriel, Wolfgang M. Schaefer,

Gynecological Endocrinology

2010

24

Ovarian transplantation for fertility preservation in a sheep model: can follicle loss be prevented by antiapoptotic sphingosine-1-phosphate administration?

Katharina Hancke, Elisabeth Walker, Oliver Strauch,

Gynecological Endocrinology

2009

24

Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles) — an open-label, prospective, noncontrolled, office-based Phase III study

H. P. Zahradnik, Aida Hanjalic-Beck

Contraception

2008

23

Potential hazards to embryo implantation: A human endometrial in vitro model to identify unwanted antigestagenic actions of chemicals

Lara Fischer, W.R. Deppert, Dietmar Pfeifer,

Toxicology and Applied Pharmacology

2012

12

Page 1